VIENNA (Reuters) - Swiss drugmaker Roche is unable to meet demand for molecular tests to identify active COVID-19 infections, its chairman told Swiss daily Tagesanzeiger.
"The demand exceeds our production," Christoph Franz was quoted as saying in Saturday's paper. The decision on where tests were shipped to depended, among other things, on infection rates and the availability of diagnostic equipment.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!